Skip to main content

Table 1 Comparison between MHT users and non-users

From: The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study

Characteristic Total (n = 133,690) MHT P
Yes (n = 22,577) No (n = 111,113)
Follow-up months, mean (SD) 74.6 (36.8) 74.4 (36.9) 74.7 (36.7) 0.2916
Age (years) n % n % n % 0.9745
 40–49 65,008 48.63 10,959 48.54 54,049 48.64  
 50–59 50,866 38.05 8590 38.05 42,276 38.05  
 60–69 12,902 9.65 2189 9.70 10,713 9.64  
 70~ 4914 3.68 839 3.72 4075 3.67  
Income level 0.4772
 ≤ 30% (low) 38,082 28.49 6425 28.46 31,657 28.49  
 31–60% 38,390 28.72 6575 29.12 31,815 28.63  
 61–90% 33,180 24.82 5555 24.60 27,625 24.86  
 ≥ 91% (high) 24,038 17.98 4022 17.81 20,016 18.01  
Region 0.7807
 Metropolitan 63,621 47.59 10,725 47.50 52,896 47.61  
 Others 70,069 52.41 11,852 52.50 58,217 52.39  
CCI < .0001
 1 45,068 33.71 8040 35.61 37,028 33.32  
 2 39,650 29.66 7364 32.62 32,286 29.06  
 3 15,894 11.89 2994 13.26 12,900 11.61  
 4 or more 33,078 24.74 4179 18.51 28,899 26.01  
Year of study entry 0.9954
 2004 19,707 14.74 3293 14.59 16,414 14.77  
 2005 18,744 14.02 3142 13.92 15,602 14.04  
 2006 16,350 12.23 2750 12.18 13,600 12.24  
 2007 17,018 12.73 2871 12.72 14,147 12.73  
 2008 14,815 11.08 2507 11.10 12,308 11.08  
 2009 10,375 7.76 1754 7.77 8621 7.76  
 2010 11,128 8.32 1891 8.38 9237 8.31  
 2011 8076 6.04 1374 6.09 6702 6.03  
 2012 9489 7.10 1623 7.19 7866 7.08  
 2013 7988 5.98 1372 6.08 7866 5.95  
  1. CCI Charlson comorbidity index, MHT menopausal hormone therapy, SD standard deviation